non glp-1 medications for weight loss Understanding Medications: vs. Phentermine Market Overview: GLP-1 Agonists and

The framework prioritised semaglutide and tirzepatide as first-line treatments, based on evidence of 15% weight loss and benefits in complications such as cardiovascular disease and sleep apnoea

IQVIA notes six big shifts in medicines use in 2023: Growing use of immunology treatments up 60% from 2019 with treatment of Crohns disease and psoriasis up 26% and 15%, respectively Rising use of novel obesity drugs which is the GLP-1 story Ill relate to the next graphic, below

Adjust early and consider clinician contact

From study baseline to the end of follow-up, GLP-1RAs treatment resulted in statistically significant decreases in weight (MD=-2.32 kg, 95% CI: -4.21 to -0.43) and BMI (MD=-0.82 kg/m2, 95% CI: -1.47 to -0.17)

A single pouch is called a diverticulum

Transdermal delivery no pills or drinks needed